StockNews.AI
SGHT
StockNews.AI
187 days

Sight Sciences to Present at Citi's 2025 Unplugged MedTech and Life Sciences Access Day

1. Sight Sciences will present at Citi's MedTech event on February 27. 2. The company's innovative eyecare tech targets prevalent eye diseases effectively. 3. Their OMNI® Surgical System aims to reduce glaucoma-related intraocular pressure. 4. SIGHT's TearCare® System is cleared for treating evaporative dry eye disease.

4m saved
Insight
Article

FAQ

Why Bullish?

Presentation at a major event can attract investor interest, similar to past announcements boosting stock prices.

How important is it?

The event might showcase advancements, potentially attracting investor interest and increasing stock valuations.

Why Short Term?

Immediate visibility from the presentation could influence trading activity shortly after.

Related Companies

SGHTGPROVRTX
February 13, 2025 16:05 ET  | Source: Sight Sciences, Inc. MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced plans to present at Citi’s 2025 Unplugged MedTech and Life Sciences Access Day, in New York, NY. Sight Sciences’ management is scheduled to present on Thursday, February 27, 2025, at 7:15 am PT / 10:15 am ET. Interested parties may access a live and archived webcast of the fireside chat on the “Investors” section of the Company’s website at https://investors.sightsciences.com/. About Sight Sciences Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION® Surgical Instrument is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (“MGD”), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information.  Sight Sciences, the Sight Sciences logo, TearCare, SmartHub and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories.   © 2025 Sight Sciences. All rights reserved.   Media contact:pr@sightsciences.com Investor contact:Philip TaylorGilmartin Group415.937.5406investor.relations@sightsciences.com

Related News